Description: Ulixertinib is an inhibitor of ERK protein kinase. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Upon oral administration, BVD-523 inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal...

Ulixertinib is a reversible ERK1/2 inhibitor that demonstrates an IC50 value of V600E mutation, it has been reported to reduce the levels of phosphorylated ERK2 and the downstream kinase RSK (IC50s = 4.1 and 0.14 µM, respectively). Ulixertinib has also been shown to inhibit A375 cell proliferation with an IC50 value...